帕利哌酮与利培酮治疗精神分裂症的临床观察 点击下载
| 论文标题： | 帕利哌酮与利培酮治疗精神分裂症的临床观察 |
| 英文标题： | |
| 中文摘要： | 目的：观察帕利哌酮与利培酮治疗精神分裂症的疗效及安全性。方法：将98例精神分裂症患者按随机数字表法分为帕利哌酮组和利培酮组，各49例。帕利哌酮组患者给予帕利哌酮初始剂量6 mg，qd，根据患者病情1周内给予3～12 mg，qd；利培酮组患者给予利培酮初始剂量1 mg，qd，根据患者病情1周内加至4～6 mg，qd。观察两组患者临床疗效及治疗前后阳性和阴性症状量表（PANSS）评分、个人和社会功能量表（PSP）评分、血清泌乳素（PRL）和脂代谢水平，并采用椎体外系副反应量表（RSESE）和治疗时出现的症状量表（TESS）进行不良反应评价。结果：两组患者临床疗效比较，差异无统计学意义（P＞0.05）。两组患者治疗前及治疗后8周PANSS总分、阳性症状、阴性症状、一般病理症状评分比较，差异无统计学意义（P＞0.05）；治疗后12周帕利哌酮组患者PANSS总分、阳性症状、阴性症状、一般病理症状评分均显著降低，且低于利培酮组，差异有统计学意义（P＜0.05）。两组患者治疗前及治疗后8周PSP评分比较，差异无统计学意义（P＞0.05）；治疗后12周，帕利哌酮组患者PSP评分显著升高，且明显高于利培酮组，差异有统计学意义（P＜0.05）。治疗后12周，两组患者血清PRL、三酰甘油（TC）、高密度脂蛋白（HDL-C）、低密度脂蛋白（LDL-C）水平均明显升高，且利培酮组明显高于帕利哌酮组，差异有统计学意义（P＜0.05）；两组患者的总胆固醇（TG）水平较治疗前显著升高，差异有统计学意义（P＜0.05），但组间比较差异无统计学意义（P＞0.05）。帕利哌酮组患者的不良反应发生率、RSESE评分和TESS评分均明显低于利培酮组，差异有统计学意义（P＜0.05）。结论：帕利哌酮与利培酮治疗精神分裂症的疗效相当，且均能显著改善患者精神症状，但帕利哌酮起效快、安全性更好。 |
| 英文摘要： | OBJECTIVE： To observe the clinical efficacy and safety of paliperidone and risperidone in the treatment of schizophrenia. METHODS： 98 patients with schizophrenia were randomly divided into paliperidone group and risperidone group， with 49 cases in each group. Paliperidone group was treated with initial dose of paliperidone with initial dose of 6 mg， qd， and then given 3-12 mg，qd， according to patient’s condition within 1 week. Risperidone group was given risperidone with initial dose of 1 mg， qd， and then given 4-6 mg， qd， according to patient’s condition within 1 week. Clinical efficacy， positive and negative PANSS， PSP， PRL and lipid metabolism level before and after treatment were observed in 2 groups. RSESE and TESS were adopted to evaluate ADR. RESULTS： There was no statistical significance in clinical efficacy between 2 groups （P＞0.05）. There was no statistical significance in total PANSS score， positive symptoms， negative symptoms and general pathological score between 2 groups before treatment and after 8 weeks treatment （P＞0.05）. Total PANSS score， positive symptoms， negative symptoms and general pathological score were reduced significantly in paliperidone group 12 weeks after treatment， and were significantly lower than risperidone group， with statistical significance （P＜0.05）. There was no statistical significance in PSP score between 2 groups before and 8 weeks after treatment （P＞0.05）； 12 weeks later， PSP score of paliperidone group increased significantly， which was significantly higher than risperidone group， with statistical significance （P＜0.05）. 12 weeks later， PRL， TC， HDL-C and LDL-C levels increased in 2 groups， and those in risperidone group were significantly higher than paliperidone group， with statistical significance （P＜0.05）； TG of 2 groups were increased significantly after treatment compared to before treatment， with statistical significance （P＜0.05）， but no statistical significance between 2 groups （P＞0.05）. The scores of RSESE and TESS of the incidence of ADR in the paliperidone group were lower than those in risperidone group， with statistical significance （P＜0.05）. CONCLUSIONS： Therapeutic efficacy of paliperidone is similar to risperidone in the treatment of schizophrenia， and both can improve mental symptom. Paliperidone has worked faster and more safely. |
| 期刊： | 2016年第27卷第11期 |
| 作者： | 贺楚梅，阳前军，王珍兰 |
| 英文作者： | HE Chumei，YANG Qianjun，WANG Zhenlan |
| 关键字： | 帕利哌酮；利培酮；精神分裂症；临床疗效；安全性 |
| KEYWORDS： | Paliperidone； Risperidone； Schizophrenia； Clinical efficacy； Safety |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！